JPS61151127A - Production of soft capsule containing bifidus bacteria - Google Patents
Production of soft capsule containing bifidus bacteriaInfo
- Publication number
- JPS61151127A JPS61151127A JP59271881A JP27188184A JPS61151127A JP S61151127 A JPS61151127 A JP S61151127A JP 59271881 A JP59271881 A JP 59271881A JP 27188184 A JP27188184 A JP 27188184A JP S61151127 A JPS61151127 A JP S61151127A
- Authority
- JP
- Japan
- Prior art keywords
- gelatin
- soft capsule
- melting point
- bifidus bacteria
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
（１）発明の目的
本願発明はビフィズス菌の乾燥菌体を皮膜材で覆うビフ
ィズス菌含有ソフトカプセルの製造方法の発明である。DETAILED DESCRIPTION OF THE INVENTION (1) Purpose of the Invention The present invention is an invention of a method for producing a soft capsule containing Bifidobacterium, which covers dried bacterial cells of Bifidobacterium with a film material.
ビフィズス菌の生理学的Ｑ義については多数の報告がな
されており、腸内腐敗の原因菌である大腸菌、ウェルシ
ュ菌、バクテロイデス菌等の増殖を抑制し、下痢、便秘
を予防し、乳酸・酢酸等の有機酸を産生し、ビタミン類
を産生ずる等力れた生理効果を有することが既に広く知
られている。There have been many reports on the physiological quality of Bifidobacterium, and it has been reported that it suppresses the growth of Escherichia coli, Clostridium perfringens, Bacteroides, etc., which are the bacteria that cause intestinal putrefaction, prevents diarrhea and constipation, and suppresses the growth of bacteria such as lactic acid and acetic acid. It is already widely known that it has powerful physiological effects such as producing organic acids and vitamins.
しかし、ビフィズス菌粉末は一般に生存性が悪く、活性
が低下しやすい。またビフィズス菌特有の臭気、保護剤
の澱粉臭などのために食感が悪かった。However, Bifidobacterium powder generally has poor survivability and tends to lose activity. In addition, the texture was poor due to the odor peculiar to bifidobacteria and the starch odor of the protective agent.
しかも、ビフィズス菌は酸性溶液中で死滅しやすく、活
性を維持したままＰＨ１，２〜５０の胃中を通過させて
腸にまで到達させることは困難であった。In addition, Bifidobacterium easily dies in acidic solutions, making it difficult to pass through the stomach at a pH of 1.2 to 50 and reach the intestines while maintaining its activity.
本願の発明者らは、これらビフィズス菌粉末の欠点を克
服し、かつビフィズス菌特有の不快臭を感じさせること
なく嗜好性が高く、かつ長期間安定生存できるビフィズ
ス菌ソフトカプセルを製造する方法を発明した。さらに
本願発明の製造方法により飲用後背中でビフィズス菌が
死滅することなり、腸にまで生きたまま到達させること
ができ、腸内でカプセルが溶解する、ビフィズス菌含有
ソフＩ・カプセルを製造することができた。The inventors of the present application have invented a method for producing Bifidobacterium soft capsules that overcome these drawbacks of Bifidobacterium powder, are highly palatable without the unpleasant odor peculiar to Bifidobacteria, and can survive stably for a long period of time. . Furthermore, by the manufacturing method of the present invention, bifidobacteria are killed on the back after drinking, and the soft I capsules containing bifidobacteria can be delivered to the intestines alive, and the capsules dissolve in the intestines. was completed.
（２） 発明の構成
本願発明は、従来のビフィズス菌粉末が有していた前起
問題点を解決するものであって、ビフィズス菌粉末に保
護剤を添加し、融点３０〜４５℃、融点幅３℃以下の硬
化油に懸濁してカプセル核液とし、ゼラチンを用いて皮
膜を形成することを特徴とするビフィズス菌含有ソフト
カプセルの製造方法を発明の構成とするものである。(2) Structure of the Invention The present invention solves the problems that conventional Bifidobacterium powders had, and includes adding a protective agent to Bifidobacterium powders, which has a melting point of 30 to 45°C and a melting point range. The present invention provides a method for producing soft capsules containing bifidobacteria, which comprises suspending the capsules in hydrogenated oil at 3° C. or lower to obtain capsule core liquid, and forming a film using gelatin.
本願発明で使用するビフィズス菌は通常のビフィズス菌
（Ｂｉｆｉｄｏｂａｅｔｅｒｉｕ＋ａＩＭり テあッテ
１これに属するビフィズス菌はいずれも使用することが
できる。その主要なものは、ビフィドバクテリウム 四
ンガム（Ｂｉｆｉｄｏｂａｅｔｅｒｉｕａ＋１ｏｎｇｕ
鵬）、ビフィドバクテリウム インファノテス（Ｂｉｆ
ｉｄｏｂａｅｔｅｒｉｕｍ １ｎｆａｎｔｉｓ） 、ビ
フィドバクテリウム アドレッセンテス（Ｂｉｆｉｄ。The Bifidobacterium used in the present invention can be any of the normal Bifidobacteria (Bifidobacteria).
Peng), Bifidobacterium infantes (Bif
idobaeterium 1nfantis), Bifidobacterium adressentes (Bifid.
ｂａｃｔｅｒｉｕｍ ａｄｏｌｅｓｃｅｎｔｉｓ）
、ビフィドバクテリウム ブレーベ（Ｂｉｆｉｄｏｂａ
ｅｔｅｒｉｕｍ ｂｒｅｖｅ）等である。bacterium adolescentis)
, Bifidobacterium breve
eterium breve) etc.
ビフィズス菌粉末には保護剤を添加するが、これには例
えば澱粉と（に乾燥澱粉を用いることが望ましい。A protective agent is added to the bifidobacterium powder, and it is preferable to use, for example, starch and dried starch.
保護剤はビフィズス菌の凍結乾燥前に添加するが、凍結
乾燥後に水分活性を０．２以下にして添加してもよい。The protective agent is added before freeze-drying the Bifidobacterium, but may be added after freeze-drying to reduce the water activity to 0.2 or less.
保護剤を添加したビフィズス菌粉末を、融点が３０〜４
５℃、融点幅３℃以下の硬化油融点範囲の狭い硬化油を
使用することにより、懸濁液を直ちに固化することがで
きる。Bifidobacterium powder added with a protective agent has a melting point of 30 to 4.
By using a hardened oil with a narrow melting point range of 5° C. and a melting point width of 3° C. or less, the suspension can be immediately solidified.
これにより皮膜液中の水分が懸濁液へ移行することを防
ぎ、ビフィズス菌の生存率を高めることができる。This prevents the moisture in the coating solution from transferring to the suspension, thereby increasing the survival rate of the bifidobacteria.
ビフィズス菌粉末の量は、使用する硬化油量の３０％以
下、好ましくは２５％以下である。The amount of bifidobacteria powder is 30% or less, preferably 25% or less of the amount of hydrogenated oil used.
ビフィズス菌粉末と油脂との混合は、油脂の融点より２
〜５℃高い温度で行う。The mixing of bifidobacterium powder and fat is 2 times higher than the melting point of the fat.
Perform at ~5°C higher temperature.
他方、皮膜液にはゼラチン溶液を使用する。On the other hand, a gelatin solution is used as the coating solution.
ゼラチン溶液の固形分は２０〜３５％が望ましく、また
ゼラチンにはペクチンを添加することが好ましく、その
ペクチン添加量はゼラチン量の５〜２０％が適量である
。The solid content of the gelatin solution is preferably 20 to 35%, and it is preferable to add pectin to gelatin, and the appropriate amount of pectin added is 5 to 20% of the amount of gelatin.
ペクチンとともに、またはペクチンにかえて、アルギン
酸ナトリウムを添加することもできる。Sodium alginate can also be added together with or instead of pectin.
カプセルの形成には公知の方法を用いるこ＞＋ｔＦｈｋ
Ｘ−＠（げ−７’Ｉｔ轡ｔｑ−＋１−（ｔｋ）−＼１Ｉ
ｆｌＦ＋１−８８７５号）を使用し、外管ノズルに皮膜
液を、内管ノズルに植設を流し、冷却した油中に滴下す
ることによりゼラチンが固化し、カプセルが形成される
。次に、カプセルから冷却に使用した油を除去し、乾燥
する。A known method can be used to form the capsule>+tFhk
X-@(ge-7'It轡tq-+1-(tk)-\1I
flF+1-8875), the coating liquid is poured into the outer tube nozzle and the implantation is poured into the inner tube nozzle, and the gelatin is solidified by dropping into the cooled oil to form a capsule. The oil used for cooling is then removed from the capsules and the capsules are dried.
さらに、特開昭５８−１７２．３１３号記載の方法によ
りカルシウム液に浸漬して腸溶化処理し、取り出した後
皮膜の水分が８〜１５％になるように乾燥する。Furthermore, it is immersed in a calcium solution for enteric treatment according to the method described in JP-A-58-172.313, and after being taken out, it is dried so that the moisture content of the film is 8 to 15%.
ペクチンがカルシウムと反応して凝固し、酸に安定な皮
膜が形成される。Pectin reacts with calcium and coagulates, forming an acid-stable film.
これによりビフィズス菌含有ソフトカプセルが得られた
。As a result, soft capsules containing bifidobacteria were obtained.
このカプセルは日本薬局方の崩壊試験法にもとづ＜１１
％溶性試験に合格し、胃中では溶解せず、腸で溶解する
ことが明らかとなった。This capsule is based on the disintegration test method of the Japanese Pharmacopoeia.
It passed the % solubility test, revealing that it does not dissolve in the stomach but dissolves in the intestines.
（３）実施例
ココナツツオイルおよびパームカーネルオイルを主原料
とする硬化油（融点範囲３３〜３５℃、沃素価２以下）
８０部を３８℃に保持し、これに凍結乾燥したビフィド
バクテリ’）ム Ｏンガム（Ｂｉｆｉｄｏｂａｃｔｅｒ
ｉｕｍ Ｉｏｎｇｕｍ）１部に対し、乾燥馬鈴薯澱粉（
水分活性０．１５）９部を混合したもの２０部を懸濁し
、これを植設とした。(3) Example Hydrogenated oil whose main ingredients are coconut oil and palm kernel oil (melting point range: 33-35°C, iodine value: 2 or less)
80 parts were kept at 38°C, and lyophilized Bifidobacterium gum (Bifidobacterium) was added to this.
1 part of dried potato starch (
20 parts of a mixture of 9 parts with a water activity of 0.15) was suspended and used as an implant.
他方、皮膜液はゼラチン７５部、グリセリン５部、ペク
チン１０部の割合で、かつ固形分が２８％になるように
調整し、３８℃の温湯に溶解した。On the other hand, the coating liquid was adjusted to have a ratio of 75 parts of gelatin, 5 parts of glycerin, and 10 parts of pectin, and the solid content was 28%, and dissolved in hot water at 38°C.
二重管ノズルを使用し、その外管に皮膜液を、内管に植
設を通し、冷却した油（植物油等）中に滴下して平均直
径６ｍ５ｉのビフィズス菌含有ソフトカプセルを得た。Using a double tube nozzle, the coating liquid was passed through the outer tube and the implant through the inner tube, and dropped into cooled oil (vegetable oil, etc.) to obtain bifidobacteria-containing soft capsules with an average diameter of 6 m5i.
次に腸溶化処理のためカプセルを５％塩化カルシウム液
に浸漬し、取り出した後冷風で乾燥した。これにより皮
膜の水分が１１％のカプセルを得た。Next, the capsules were immersed in a 5% calcium chloride solution for enteric treatment, taken out, and dried with cold air. This gave capsules with a film moisture content of 11%.
このカプセルには？、３ＸＩＱ７個／ｇのビフィドバク
テリウム ロンガムが生存していた。What about this capsule? , 3XIQ 7 pieces/g of Bifidobacterium longum were found to be alive.
（４） 生存実験
前記実施例により製造したソフ】・カプセルについて生
存実験を行った。(4) Survival Experiment A survival experiment was conducted on the soft capsules produced in the above example.
その結果、６ケ月を経過してもカプセル中のビフィズス
菌の菌数の減少は僅少であり、生存性が極めて高いこと
が判明した。As a result, it was found that even after 6 months, the number of Bifidobacterium bacteria in the capsule decreased only slightly, indicating extremely high survivability.
（５）崩壊試験
前記実施例により製造したソフトカプセルについて崩壊
試験を行った。(5) Disintegration test A disintegration test was conducted on the soft capsules produced according to the above example.
崩壊試験は、日本薬局方筒中改正登載のｒ 昂塘すぎ仝
９土ｔｃ＋ ｔｔ厘釦〜鮪 へ釦ｌ餉ｌ −−・、
・ −・−び頴粒状の形で充てんしたカプセル剤以外の
製剤」の試験法にもとづいて行った。The disintegration test was carried out using the Japanese Pharmacopoeia, revised version of the Japanese Pharmacopoeia.
The test was conducted based on the test method for "Preparations other than capsules filled in the form of granules."
塩化ナトリウム２．０ｇに希塩酸２４．０ｍｌ及び水を
加えて１０１００Ｏとしたものを第１液（ｐＨ１，２）
、！：Ｉ、、０ 、２ Ｍ ’Ｊ ン峻二水素カリウム
試液２５ｏ１に０．２Ｎ水酸化ナトリウム試液１１８１
及び水を加えて１０１００Ｏとしたものを第２液（ｐＨ
６、８）とした。The first solution (pH 1, 2) was made by adding 24.0 ml of dilute hydrochloric acid and water to 2.0 g of sodium chloride to make it 10,100 O.
,! :I,,0,2M'J 0.2N sodium hydroxide test solution 1181 to 25o1 potassium dihydrogen test solution
The second solution (pH
6, 8).
ソフトカプセルは第１液中では１２０分経過しても全く
異常がなく、第２液中テハ１゜分径に全て溶解した。There was no abnormality in the soft capsules in the first liquid even after 120 minutes, and all of the soft capsules dissolved in the second liquid to a diameter of 1°.
これによりソフトカプセルは日本薬局方の崩壊試験法に
もとづ＜１ＩＪＦ性試験に適合し、合格した。As a result, the soft capsule met and passed the <1IJF property test based on the disintegration test method of the Japanese Pharmacopoeia.
（６）効果
本願発明の製造方法により、ビフィズス閑含有ソフトカ
プセルを製造することができる。(6) Effects By the production method of the present invention, soft capsules containing bifidus can be produced.
これにより、ビフィズス菌特有の不快臭や保護剤の澱粉
臭を感じさせることなく、嗜好性また、本願発明の方法
によって製造したソフトカプセルは長期間安定生存する
ことができ、カプセル中のビフィズス菌の生存率は極め
て高かった。As a result, the soft capsules produced by the method of the present invention can survive stably for a long period of time without giving rise to the unpleasant odor peculiar to bifidobacteria or the starch odor of the protective agent. The rate was extremely high.
さらに、本願発明の方法により、ビフィズス菌が胃中で
死滅せず、腸にまで生存したまま到達する、ビフィズス
菌含有ソフトカプセルを製造することができた。Furthermore, by the method of the present invention, it was possible to produce a soft capsule containing Bifidobacterium in which the Bifidobacterium does not die in the stomach and reaches the intestines alive.
Claims (7)
４５℃、融点幅３℃以下の硬化油に懸濁してカプセル核
液とし、ゼラチンを用いて皮膜を形成することを特徴と
するビフィズス菌含有ソフトカプセルの製造方法(1) Add a protective agent to Bifidobacterium powder, melting point 30~
A method for producing soft capsules containing bifidobacteria, which comprises suspending them in a hydrogenated oil with a melting point width of 3°C or less at 45°C to form a capsule core liquid, and forming a film using gelatin.
ィズス菌含有ソフトカプセルの製造方法(2) Method for producing soft capsules containing bifidobacteria according to claim 1, using starch as a protective agent
許請求の範囲第１項のビフィズス菌含有ソフトカプセル
の製造方法(3) The method for producing soft capsules containing bifidobacteria according to claim 1, in which a protective agent is added before freeze-drying the bifidobacteria.
０．２以下にて添加する特許請求の範囲第１項のビフイ
ズス菌含有ソフトカプセルの製造方法(4) The method for producing soft capsules containing bifidobacteria according to claim 1, wherein the protective material is added at a water activity of 0.2 or less after freeze-drying the bifidobacteria.
許請求の範囲第１項のビフィズス菌含有ソフトカプセル
の製造方法(5) A method for producing a soft capsule containing bifidobacteria according to claim 1, in which the solid content of the gelatin film liquid is 20 to 35%.
ギン酸ナトリウムを添加してカプセル化し、カプセル化
後にカルシウム塩溶液に浸漬する特許請求の範囲第１項
のビフィズス菌含有ソフトカプセルの製造方法(6) A method for producing a soft capsule containing bifidobacteria according to claim 1, which comprises adding pectin and/or sodium alginate to a gelatin film solution, encapsulating the liquid, and immersing it in a calcium salt solution after encapsulation.
ンの５〜２０％である特許請求の範囲第１項又は第６項
のビフィズス菌含有ソフトカプセルの製造方法(7) The method for producing a soft capsule containing bifidobacteria according to claim 1 or 6, wherein the pectin added to the gelatin film liquid is 5 to 20% of the gelatin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59271881A JPS61151127A (en) | 1984-12-25 | 1984-12-25 | Production of soft capsule containing bifidus bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59271881A JPS61151127A (en) | 1984-12-25 | 1984-12-25 | Production of soft capsule containing bifidus bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61151127A true JPS61151127A (en) | 1986-07-09 |
| JPH0568446B2 JPH0568446B2 (en) | 1993-09-29 |
Family
ID=17506203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59271881A Granted JPS61151127A (en) | 1984-12-25 | 1984-12-25 | Production of soft capsule containing bifidus bacteria |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61151127A (en) |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62263128A (en) * | 1986-05-08 | 1987-11-16 | Freunt Ind Co Ltd | Capsule containing useful enteric bacteria |
| JPH0395122A (en) * | 1990-04-25 | 1991-04-19 | Freunt Ind Co Ltd | Enteric useful bacteria-containing composition |
| EP0634167A1 (en) * | 1993-07-08 | 1995-01-18 | Morishita Jintan Co., Ltd. | Process for producing capsule and capsule obtained thereby |
| US6447823B1 (en) | 1997-10-14 | 2002-09-10 | Bing-Grae Co., Ltd. | Liquid yogurt with encapsulated lactic acid bacteria and method for producing the same |
| KR100777210B1 (en) | 2006-05-29 | 2007-11-28 | (주)케비젠 | The method of preparing lactic acid bacteria-unsaturated fatty acid microcapsule-krill powder, the powder prepared by the method, and the spices comprising the powder |
| WO2008114889A1 (en) * | 2007-03-19 | 2008-09-25 | Morishita Jintan Co., Ltd. | Oral vaccine |
| WO2009142170A1 (en) * | 2008-05-19 | 2009-11-26 | 森下仁丹株式会社 | Seamless capsule |
| EP2279659A3 (en) * | 2001-06-28 | 2011-02-23 | Morishita Jintan Co., Ltd. | Capsules containing vital cells or tissues |
| CN102948479A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Method for preparing milk beverage containing Bifidobacterium microcapsules |
| JP2015140315A (en) * | 2014-01-29 | 2015-08-03 | 中日本カプセル 株式会社 | filling composition for soft capsules |
| WO2015115072A1 (en) | 2014-01-31 | 2015-08-06 | 富士カプセル株式会社 | Capsule formulation |
| JP2015189684A (en) * | 2014-03-27 | 2015-11-02 | 中日本カプセル 株式会社 | Soft capsule coating and soft capsule |
| WO2021152869A1 (en) * | 2020-01-28 | 2021-08-05 | ナットリオミックス，インコーポレイテッド | Enteric composition, food/beverage item containing said enteric composition, method for controlling disintegration time for said enteric composition, and method for manufacturing said enteric composition |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104856050B (en) * | 2014-02-24 | 2017-05-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | Preparation method of probiotics gel particles |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS518875A (en) * | 1974-07-10 | 1976-01-24 | Hitachi Ltd | DENSHISENROKOSOCHI |
| JPS5524110A (en) * | 1978-08-09 | 1980-02-21 | Nippon B C G Seizo Kk | Oral capsules and their preparation |
| JPS5544725A (en) * | 1978-09-27 | 1980-03-29 | Chiyou Lsi Gijutsu Kenkyu Kumiai | Semiconductor device and its manufacture |
| JPS58172313A (en) * | 1982-04-01 | 1983-10-11 | Morishita Jintan Kk | Enteric soft capsule |
| JPS594976A (en) * | 1982-06-30 | 1984-01-11 | Nippon Kokan Kk <Nkk> | Controlling of copying welding |
| JPS6139925A (en) * | 1984-07-31 | 1986-02-26 | Tohoku Metal Ind Ltd | Magnetic recording medium |
-
1984
- 1984-12-25 JP JP59271881A patent/JPS61151127A/en active Granted
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS518875A (en) * | 1974-07-10 | 1976-01-24 | Hitachi Ltd | DENSHISENROKOSOCHI |
| JPS5524110A (en) * | 1978-08-09 | 1980-02-21 | Nippon B C G Seizo Kk | Oral capsules and their preparation |
| JPS5544725A (en) * | 1978-09-27 | 1980-03-29 | Chiyou Lsi Gijutsu Kenkyu Kumiai | Semiconductor device and its manufacture |
| JPS58172313A (en) * | 1982-04-01 | 1983-10-11 | Morishita Jintan Kk | Enteric soft capsule |
| JPS594976A (en) * | 1982-06-30 | 1984-01-11 | Nippon Kokan Kk <Nkk> | Controlling of copying welding |
| JPS6139925A (en) * | 1984-07-31 | 1986-02-26 | Tohoku Metal Ind Ltd | Magnetic recording medium |
Cited By (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62263128A (en) * | 1986-05-08 | 1987-11-16 | Freunt Ind Co Ltd | Capsule containing useful enteric bacteria |
| JPH0395122A (en) * | 1990-04-25 | 1991-04-19 | Freunt Ind Co Ltd | Enteric useful bacteria-containing composition |
| EP0634167A1 (en) * | 1993-07-08 | 1995-01-18 | Morishita Jintan Co., Ltd. | Process for producing capsule and capsule obtained thereby |
| US5478570A (en) * | 1993-07-08 | 1995-12-26 | Morishita Jintan Co., Ltd. | Process for producing capsule and capsule obtained thereby |
| US6447823B1 (en) | 1997-10-14 | 2002-09-10 | Bing-Grae Co., Ltd. | Liquid yogurt with encapsulated lactic acid bacteria and method for producing the same |
| EP2279659A3 (en) * | 2001-06-28 | 2011-02-23 | Morishita Jintan Co., Ltd. | Capsules containing vital cells or tissues |
| US8859853B2 (en) | 2001-06-28 | 2014-10-14 | Morishita Jintan Co., Ltd | Capsules containing vital cells or tissues |
| KR100777210B1 (en) | 2006-05-29 | 2007-11-28 | (주)케비젠 | The method of preparing lactic acid bacteria-unsaturated fatty acid microcapsule-krill powder, the powder prepared by the method, and the spices comprising the powder |
| WO2008114889A1 (en) * | 2007-03-19 | 2008-09-25 | Morishita Jintan Co., Ltd. | Oral vaccine |
| JP5187642B2 (en) * | 2007-03-19 | 2013-04-24 | 森下仁丹株式会社 | Oral vaccine |
| US8758760B2 (en) | 2007-03-19 | 2014-06-24 | Morishita Jintan Co., Ltd. | Oral vaccine |
| WO2009142170A1 (en) * | 2008-05-19 | 2009-11-26 | 森下仁丹株式会社 | Seamless capsule |
| CN102948479A (en) * | 2012-11-19 | 2013-03-06 | 陕西科技大学 | Method for preparing milk beverage containing Bifidobacterium microcapsules |
| JP2015140315A (en) * | 2014-01-29 | 2015-08-03 | 中日本カプセル 株式会社 | filling composition for soft capsules |
| WO2015115072A1 (en) | 2014-01-31 | 2015-08-06 | 富士カプセル株式会社 | Capsule formulation |
| JP2015189684A (en) * | 2014-03-27 | 2015-11-02 | 中日本カプセル 株式会社 | Soft capsule coating and soft capsule |
| WO2021152869A1 (en) * | 2020-01-28 | 2021-08-05 | ナットリオミックス，インコーポレイテッド | Enteric composition, food/beverage item containing said enteric composition, method for controlling disintegration time for said enteric composition, and method for manufacturing said enteric composition |
| JP2021114952A (en) * | 2020-01-28 | 2021-08-10 | ナットリオミックス, インコーポレイテッドNutriomix, Inc. | Enteric composition, food/beverage containing enteric composition, method for controlling disintegration time for enteric composition, and method for manufacturing enteric composition |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0568446B2 (en) | 1993-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3752421B2 (en) | Fine enteric coated granules for stabilization of lactic acid bacteria | |
| JPS61151127A (en) | Production of soft capsule containing bifidus bacteria | |
| JP4995407B2 (en) | Chewable soft capsule | |
| CA2341024C (en) | Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture | |
| CA2303852C (en) | Fish gelatin compositions containing a hydrocolloid setting system | |
| EP0610178B1 (en) | Therapeutical composition and process for its preparation | |
| JPH0213350A (en) | Sugarless pectin delivery system | |
| AU2012374707B2 (en) | Capsule disintegrable in large-intestine-specific manner | |
| KR102519593B1 (en) | enteric capsules | |
| CN106456558A (en) | Method of producing enteric soft capsule | |
| US3826666A (en) | Enteric capsules | |
| JPH0482827A (en) | Entero-soluble capsule | |
| JPH11302158A (en) | Health food having intestinal function controlling action and produced by using enteric seam capsule | |
| KR20210123989A (en) | Method for producing soft capsule type functional health food | |
| JP2017149681A (en) | Large intestine delivery capsule formulation | |
| JPH05186337A (en) | Enteric granule composed of multiple granules | |
| JPH03988B2 (en) | ||
| JP4457641B2 (en) | Gelatin capsule | |
| JP2519485B2 (en) | Method for manufacturing capsule body with thin coating | |
| WO1989005630A1 (en) | Oral dosage units for pharmaceuticals and their use and preparation | |
| CN113747886A (en) | Novel specific water-soluble vitamin delivery system | |
| JPH05186335A (en) | Enteric particle | |
| JP2000327569A (en) | Intraintestinal environment ameliorator | |
| CN104957346A (en) | Degradable environment-friendly chewing gum and preparation method thereof | |
| JP4388607B2 (en) | Casein hard capsule and method for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |